Profile data is unavailable for this security.
About the company
Magforce AG is a Germany-based company engaged in the provision of nanotechnology solutions for health sector. Its non-invasive technology uses magnetic nanoparticles to combat tumors, without harmful effect on the healthy tissues. The Company's range of treatment products includes NanoTherm Therapie for treating tumors locally; NanoTherm, a fluid containing ferrous oxide molecules that penetrate deeply into the tumor tissues and reacting to the presence of a magnetic field; NanoActivator, which are iron oxide nanoparticles for tumors in all areas of the body, and NanoPlan, a software platform that facilitates therapy planning and adjusts proper temperatures for the treatment and and the necessary magnetic field strength. As of December 31, 2011, Nanostart AG held a 49.6%-stake in the Company.
- Revenue in EUR (TTM)351.98k
- Net income in EUR-10.57m
- Incorporated2005
- Employees69.00
- LocationMagforce AGMax-Planck-Strasse 3BERLIN 12489GermanyDEU
- Phone+49 303083800
- Fax+49 3 030838099
- Websitehttps://www.magforce.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MagForce AG | 351.98k | -10.57m | 179.59k | 69.00 | -- | 0.0067 | -- | 0.5102 | -0.3531 | -0.3531 | 0.0118 | 0.8967 | 0.0055 | 3.47 | 0.8532 | 5,101.16 | -16.47 | -3.78 | -31.53 | -6.78 | -89.95 | 25.30 | -3,004.22 | -295.23 | 0.0321 | -1.97 | 0.2485 | -- | -43.33 | -5.77 | -171.71 | -- | -- | -- |
| bioXXmed AG | 3.49k | -996.91k | 336.03k | 1.00 | -- | 1.05 | -- | 96.28 | -5.23 | -5.23 | 0.0176 | 1.17 | 0.006 | -- | 0.0572 | 3,490.00 | -170.22 | -39.81 | -206.00 | -40.13 | -- | -- | -28,564.76 | -25,207.92 | -- | -6.95 | 0.00 | -- | -79.94 | -37.36 | 95.24 | -- | -- | -- |
| Oxurion NV | 2.00k | 1.96m | 420.59k | 11.00 | 0.0098 | -- | 0.2075 | 210.30 | 0.6137 | 0.6137 | 0.0006 | -3.76 | 0.0004 | -- | 0.0015 | 181.82 | 41.10 | -101.52 | -- | -249.96 | -650.00 | 53.85 | 97,950.00 | -2,672.68 | -- | -- | -- | -- | -98.86 | -76.22 | 100.63 | -- | -- | -- |
| MediGene AG | -100.00bn | -100.00bn | 598.48k | 87.00 | -- | 0.0301 | -- | -- | -- | -- | -- | 1.33 | -- | -- | -- | -- | -- | -22.31 | -- | -25.28 | -- | 90.15 | -- | -123.17 | -- | -- | 0.1146 | -- | -80.69 | -4.89 | -94.20 | -- | -8.12 | -- |
| PCI Biotech Holding ASA | 415.84k | -1.82m | 715.16k | 7.00 | -- | 0.6442 | -- | 1.72 | -0.5502 | -0.5502 | 0.1256 | 0.3353 | 0.1676 | -- | 0.896 | 669,714.30 | -73.44 | -41.44 | -92.22 | -46.61 | -- | -- | -438.10 | -897.91 | -- | -- | 0.022 | -- | 125.25 | -6.43 | 19.19 | -- | -- | -- |
| Epigenomics AG | 4.00k | -2.76m | 762.95k | 3.00 | -- | -- | -- | 190.74 | -3.14 | -3.14 | 0.0046 | 0.00 | 0.0003 | -- | -- | 2,000.00 | -23.10 | -55.09 | -23.17 | -61.61 | -2,300.00 | -0.2095 | -69,025.00 | -473.65 | -- | -- | 1.00 | -- | -100.00 | -- | 24.90 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 31 Dec 2024 | 2.94m | 9.83% |
| Ruffer LLPas of 31 Oct 2025 | 112.03k | 0.37% |
